The aim of this study was to compare the effects of adding semaglutide versus sitagliptin onto metformin with or without a sulfonylurea in type 2 diabetes (T2D). The main finding was that adding 7mg or 14mg semaglutide on to metformin/sulphonylurea therapy showed greater improvements in blood sugar control compared to sitagliptin.

This study investigated the safety and effectiveness of sarilumab (Kevzara) compared to other drugs in rheumatoid arthritis (RA). They found that sarilumab is similarly or more effective than other RA drugs.

The aim of this study was to investigate blood glucose control and rates of hypoglycemia (dangerously low blood glucose levels) when diabetic patients were switched from their basal insulin to insulin degludec (Tresiba). The main finding of this study was that patients who were switched to insulin degludec had improved blood glucose control without increasing hypoglycemia risk.

This study investigated whether exposure to tumor necrosis factor alpha (TNFalpha) inhibitors increases the risk of herpes zoster (shingles) in rheumatoid arthritis patients.

The aim of this study was to compare the cost-effectiveness of semaglutide (Ozempic) to extended-release (ER) exenatide (Byetta, Bydureon) and dulaglutide (Trulicity) ?in the treatment of type 2 diabetes (T2D). The main finding of the study was that once-weekly semaglutide was more cost-effective than exenatide and dulaglutide.

This study investigated the benefits of water therapy for rheumatoid arthritis patients with fibromyalgia.

The aim of this study was to investigate the association between uric acid levels and the risk of heart and kidney disease in type 1 diabetes (T1D). The main finding was that patients with high uric acid levels had a higher risk of kidney disease, heart attacks, strokes, and death.

This trial is examining the safety and effectiveness of new dressing ALLO-ASC-SHEET in the treatment of diabetic foot ulcers. The main outcome to be measured will be the number of patients with completely healed ulcers. This trial is recruiting in California, the United States.

This study examined how effective tofacitinib (Xeljanz) is as a treatment for early stage rheumatoid arthritis. The authors concluded that tofacitinib treatment on its own or in conjunction with methotrexate (Trexall) can reduce inflammation and can slow disease progression. 

This study aimed to investigate the relationship between magnesium and the risk of heart disease in type 2 diabetes (T2D). The main finding of the study is that higher magnesium intake, a higher rate of magnesium removal from the body and higher blood magnesium levels were associated with lower rates of heart disease in T2D.